CytoMed Therapeutics (CytoMed Therapeutics) EBIT : $-3.05 Mil (TTM As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is CytoMed Therapeutics EBIT?

CytoMed Therapeutics's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2023 was $-1.47 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.05 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. CytoMed Therapeutics's annualized ROC % for the quarter that ended in Dec. 2023 was -114.83%. CytoMed Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -152.39%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. CytoMed Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -17.38%.

CytoMed Therapeutics EBIT Historical Data

The historical data trend for CytoMed Therapeutics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytoMed Therapeutics EBIT Chart

CytoMed Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

EBIT

-1.37

-1.42

-2.22

-3.06

CytoMed Therapeutics Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBIT	Get a 7-Day Free Trial			-0.71	-0.67	-1.53	-1.57	-1.47

Competitive Comparison of CytoMed Therapeutics's EBIT

For the Biotechnology subindustry, CytoMed Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CytoMed Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CytoMed Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where CytoMed Therapeutics's EV-to-EBIT falls into.

CytoMed Therapeutics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-3.05 Mil.

CytoMed Therapeutics (NAS:GDTC) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

CytoMed Therapeutics's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	-2.598 * ( 1 - -0.07% )	/	( (2.387	+	2.141)	/ 2 )
=	-2.5998186	/	2.264
=	-114.83 %

where

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	10.337	-	0.196	-	( 7.754	-	max(0, 0.234	-	8.52	+	7.754	))
=	2.387

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	9.285	-	0.392	-	( 6.752	-	max(0, 0.538	-	7.58	+	6.752	))
=	2.141

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

CytoMed Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-2.948	/	( ( (1.644 + max(0.509, 0))	+	(1.55 + max(0.166, 0)) )	/	2 )
=	-2.948	/	( ( 2.153	+	1.716 )	/	2 )
=	-2.948	/	1.9345
=	-152.39 %

where Working Capital is:

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.713)	-	(0.196	+	0.007	+	0.001)
=	0.509

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.674)	-	(0.392	+	0.006	+	0.11)
=	0.166

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

CytoMed Therapeutics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	-3.047	/	17.533
	=	-17.38 %

CytoMed Therapeutics EBIT Related Terms

Thank you for viewing the detailed overview of CytoMed Therapeutics's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

CytoMed Therapeutics (CytoMed Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytoMed Therapeutics Ltd (NAS:GDTC) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

F98:Germany

Address

1 Commonwealth Lane, No. 08-22 One Commonwealth, Singapore, SGP, 149544

Website

https://w2.cytomed.sg

CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies into creating novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is majority revenue generator.

Executives

Chee Kong Choo	director, 10 percent owner	COMMONWEALTH LANE 08-22, SINGAPORE U0 149544
Jieming Zeng	director, officer: CSO and CMO	1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Shu Wang	10 percent owner	1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Wee Kiat Tan	director, officer: Chief Operating Officer	1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Keng Kiat Toh	director	1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Glorious Finance Ltd	10 percent owner	18 NAMLY GROVE SOUTH, SINGAPORE U0 267310
Luk Lucas Tien Wee	director, officer: Chief Clinical Officer	1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Leong Mark Kei Wei	director	1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Chak Hua Yew	director	1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Yuin Han Loh	director	1 COMMONWEALTH LANE 08-22, SINGAPORE U0 149544